Citigroup keeps Sepracor at buy

Sepracor Inc. was maintained at buy by Citigroup analyst Andrew Swanson after the company reported a $0.20 loss per share in the third quarter, exceeding Citigroup's forecast of a $0.65 loss. Sales of Sepracor's Lunestra and Xopenex were strong, and adjusting for market growth and an increased pills-per-script assumption, drove 2006 sales forecasts up to $663 million from $488 million and the target price to $75 from $70. Shares of the Marlborough, Mass.-based pharmaceutical company were up $0.30, or 0.53%, at $57.40 on volume of 1,731,028 shares versus the three-month running average of 1,965,820 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.